Drug intelligence / Profile preview

CP113

Development stage: Preclinical
Lead developer: Consegna Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

CP113 is a preclinical-stage long-acting injectable (LAI) small molecule being developed by Consegna Pharma for psychiatric indications. The formulation is designed to provide sustained therapeutic levels over a 28-day period. While the specific active pharmaceutical ingredient and biological target are proprietary and have not been disclosed, the program leverages Consegna's expertise in long-acting delivery technologies to improve treatment adherence in mental health.

Beyond the preview

Go deeper on CP113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP113.

Explore the full profile